Simonen Piia P, Gylling Helena, Miettinen Tatu A
Department of Medicine, Division of Internal Medicine, University of Helsinki, Biomedicum Helsinki, C4 22, P.O. BOX 700, FIN-00029 HUS, Helsinki, Finland.
Atherosclerosis. 2007 Sep;194(1):222-9. doi: 10.1016/j.atherosclerosis.2006.07.030. Epub 2006 Sep 11.
Lipoprotein distribution of non-cholesterol sterols was studied to evaluate in which lipoproteins they are carried in type 2 diabetes with body weight ranging from normal to overweight.
Serum and lipoprotein squalene and non-cholesterol sterols were quantitated with gas-liquid chromatography in 33 diabetic subjects separated into normal (BMI < or = 25 kg/m2, n=10) and overweight (BMI > 25 kg/m2, n=23) groups.
Two-thirds of the non-cholesterol sterols were carried in LDL and one-fifth in HDL, whereas squalene was mainly in VLDL and LDL in both groups. In overweight versus normal weight subjects, the absorption marker concentrations and ratios to cholesterol in serum and lipoproteins were lower and those of synthesis higher. In both groups the synthesis and absorption markers were interrelated in all lipoproteins suggesting intact regulation of cholesterol metabolism. The absorption marker ratios to cholesterol were mostly carried in HDL (cholestanol) and IDL (campesterol and sitosterol), and synthesis markers in VLDL and IDL regardless of overweight. Synthesis marker ratios were underestimated in serum versus VLDL and IDL, and those of absorption markers in serum versus IDL and HDL (p<0.05 for all). Squalene was related to lathosterol in all lipoprotein fractions (e.g., in LDL r=+0.501, p<0.01) suggesting that in diabetes squalene, too, is an indicator of cholesterol synthesis.
The absorption sterols are carried in IDL and HDL, and the synthesis markers in VLDL and IDL regardless of weight. The lipoprotein squalene and non-cholesterol sterol ratios were under- or overestimated in serum, and whether their evaluation in lipoproteins versus in serum only gives better information on cholesterol metabolism should be investigated further also in normal population.
研究非胆固醇甾醇的脂蛋白分布,以评估在体重从正常到超重的2型糖尿病患者中,它们存在于哪些脂蛋白中。
采用气液色谱法对33例糖尿病患者的血清、脂蛋白角鲨烯和非胆固醇甾醇进行定量分析,这些患者被分为正常体重组(BMI≤25kg/m²,n = 10)和超重组(BMI>25kg/m²,n = 23)。
三分之二的非胆固醇甾醇存在于低密度脂蛋白(LDL)中,五分之一存在于高密度脂蛋白(HDL)中,而两组中的角鲨烯主要存在于极低密度脂蛋白(VLDL)和LDL中。与正常体重受试者相比,超重受试者血清和脂蛋白中吸收标志物的浓度以及与胆固醇的比值较低,而合成标志物的浓度及比值较高。在两组中,所有脂蛋白的合成和吸收标志物均相互关联,提示胆固醇代谢调控完整。吸收标志物与胆固醇的比值大多存在于HDL(胆甾烷醇)和中间密度脂蛋白(IDL)(菜油甾醇和谷甾醇)中,而合成标志物存在于VLDL和IDL中,与体重无关。血清中合成标志物的比值相对于VLDL和IDL被低估,而血清中吸收标志物的比值相对于IDL和HDL被低估(所有p均<0.05)。在所有脂蛋白组分中,角鲨烯与羊毛甾醇相关(例如,在LDL中r = +0.501,p<0.01),提示在糖尿病中角鲨烯也是胆固醇合成的一个指标。
无论体重如何,吸收甾醇存在于IDL和HDL中,合成标志物存在于VLDL和IDL中。血清中脂蛋白角鲨烯和非胆固醇甾醇的比值被低估或高估,在正常人群中也应进一步研究,仅在脂蛋白中评估它们与仅在血清中评估相比,是否能更好地反映胆固醇代谢情况。